Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases.
Peripheral cytopenias are common in patients with agnogenic myeloid metaplasia (AMM). They are an important cause of morbidity and mortality, and their treatment is difficult. We report on 4 patients with AMM and severe cytopenia treated with danazol (400-600 mg/ day). Three of them became independent of red blood cell (RBC) transfusion, while the other had a slight reduction in RBC requirement. In addition, correction of thrombocytopenia and disappearance of splenomegaly were observed in 1 and 2 patients, respectively. No side effects were observed. In our experience, danazol appears effective and safe in the subset of patients with AMM whose disease is mainly characterized by bone-marrow failure. These data warrant further studies to evaluate this treatment and explore its mechanism of action.
Lévy
V
V
Service d'Hématologie, Hôtel-Dieu, Paris, France.
Bourgarit
A
A
Delmer
A
A
Legrand
O
O
Baudard
M
M
Rio
B
B
Zittoun
R
R
D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D003131:Combined Modality Therapy; D003613:Danazol / Q000627:therapeutic use*; D017707:Erythrocyte Transfusion / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy*; D013163:Splenomegaly / Q000188:drug therapy / Q000209:etiology
D003613:Danazol